Full Text View
Tabular View
No Study Results Posted
Related Studies
M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer
This study is currently recruiting participants.
Verified May 2013 by Momenta Pharmaceuticals, Inc.
Study NCT01621243   Information provided by Momenta Pharmaceuticals, Inc.

First Received on May 22, 2012.   Last Updated on May 9, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Metastatic Pancreatic Cancer
Additional conditions recognized in this trial
Pancreatic Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Neoplasms
Neoplasms by Site
Pancreatic Diseases
Interventions listed in this trial
nab-paclitaxel
gemcitabine
placebo
M402
Additional drug interventions recognized in this trial
Heparin, Low-Molecular-Weight
Paclitaxel
More general drug interventions related to this trial
Anti-Infective Agents
Anticoagulants
Antimetabolites
Antimetabolites, Antineoplastic
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Phytogenic
Antiviral Agents
Cardiovascular Agents
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Immunologic Factors
Immunosuppressive Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
Momenta Pharmaceuticals, Inc.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services